Modulating Antibody Functionality in Infectious Disease and Vaccination

Trends in Molecular Medicine

Volumn 22, Issue 11, 2016, Pages 969-982

  Gunn, Bronwyn M ^a   Alter, Galit ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

ADCC; antibodies; antibody glycosylation; Fc receptors; HIV; vaccination

Indexed keywords

FC RECEPTOR; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ANTIBODY RESPONSE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INFECTION; INNATE IMMUNITY; NONHUMAN; REVIEW; VACCINATION; ANIMAL; ANTIBODY AFFINITY; COMMUNICABLE DISEASE; COMMUNICABLE DISEASE CONTROL; HUMORAL IMMUNITY; IMMUNOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, INNATE; VACCINATION;

EID: 84992735645     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.09.002     Document Type: Review

References (102)

1. 1 Pulendran, B., Ahmed, R., Immunological mechanisms of vaccination. Nat. Immunol. 12 (2011), 509–517.
2. 2 DiLillo, D.J., et al. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126 (2016), 605–610.
3. 3 Bournazos, S., et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158 (2014), 1243–1253.
4. 4 Haynes, B.F., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366 (2012), 1275–1286.
5. 5 Kipps, T.J., et al. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. Med. 161 (1985), 1–17.
6. 6 Nimmerjahn, F., Ravetch, J.V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005), 1510–1512.
7. 7 Coutelier, J.P., et al. IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 165 (1987), 64–69.
8. 8 Beck, O.E., Distribution of virus antibody activity among human IgG subclasses. Clin. Exp. Immunol. 43 (1981), 626–632.
9. 9 Siber, G.R., et al. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N. Engl. J. Med. 303 (1980), 178–182.
10. 10 Wang, N.S., et al. Divergent transcriptional programming of class-specific B cell memory by T-bet and RORalpha. Nat. Immunol. 13 (2012), 604–611.
11. 11 Xu, Z., et al. Immunoglobulin class-switch DNA recombination: induction, targeting and beyond. Nat. Rev. Immunol. 12 (2012), 517–531.
12. 12 Pucic, M., et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol. Cell Proteomics, 10, 2011, M111010090.
13. 13 Krapp, S., et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325 (2003), 979–989.
14. 14 Sylvestre, D.L., Ravetch, J.V., Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 265 (1994), 1095–1098.
15. 15 Clynes, R., et al. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279 (1998), 1052–1054.
16. 16 Samuelsson, A., et al. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001), 484–486.
17. 17 Clynes, R.A., et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6 (2000), 443–446.
18. 18 Fukuyama, H., et al. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat. Immunol. 6 (2005), 99–106.
19. 19 McGaha, T.L., et al. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307 (2005), 590–593.
20. 20 Kaneko, Y., et al. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203 (2006), 789–797.
21. 21 Kalergis, A.M., Ravetch, J.V., Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 195 (2002), 1653–1659.
22. 22 Baudino, L., et al. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J. Immunol. 180 (2008), 1948–1953.
23. 23 Parekh, R.B., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316 (1985), 452–457.
24. 24 Rademacher, T.W., et al. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc. Natl. Acad. Sci. U.S.A. 91 (1994), 6123–6127.
25. 25 Ohmi, Y., et al. Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. Nat. Commun., 7, 2016, 11205.
26. 26 Ercan, A., et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 62 (2010), 2239–2248.
27. 27 Lauc, G., et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet., 9, 2013, e1003225.
28. 28 Wuhrer, M., et al. Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation, and sialylation. J. Proteome Res. 14 (2015), 1657–1665.
29. 29 Theodoratou, E., et al. Glycosylation of plasma IgG in colorectal cancer prognosis. Sci. Rep., 6, 2016, 28098.
30. 30 de Jong, S.E., et al. IgG1 Fc N-glycan galactosylation as a biomarker for immune activation. Sci. Rep., 6, 2016, 28207.
31. 31 Moore, J.S., et al. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 19 (2005), 381–389.
32. 32 Ackerman, M.E., et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123 (2013), 2183–2192.
33. 33 Deeks, S.G., et al. Systemic effects of inflammation on health during chronic HIV infection. Immunity 39 (2013), 633–645.
34. 34 Ackerman, M.E., et al. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgammaR2a and FcgammaR2b. J. Virol. 87 (2013), 5468–5476.
35. 35 Lai, J.I., et al. Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. J. Virol. 88 (2014), 2799–2809.
36. 36 Ackerman, M.E., et al. Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. PLoS Pathog., 12, 2016, e1005315.
37. 37 Vogt, M.R., et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J. Virol. 85 (2011), 11567–11580.
38. 38 Balachandran, N., et al. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect. Immun. 37 (1982), 1132–1137.
39. 39 Guzman, M.G., et al. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch. Virol. 158 (2013), 1445–1459.
40. 40 de Alwis, R., et al. Dengue viruses are enhanced by distinct populations of serotype cross–reactive antibodies in human immune sera. PLoS Pathog., 10, 2014, e1004386.
41. 41 Halstead, S.B., Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60 (2003), 421–467.
42. 42 Dejnirattisai, W., et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat. Immunol. 17 (2016), 1102–1108.
43. 43 Wieland, A., et al. Antibody effector functions mediated by Fcgamma-receptors are compromised during persistent viral infection. Immunity 42 (2015), 367–378.
44. 44 Yamada, D.H., et al. Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection. Immunity 42 (2015), 379–390.
45. 45 Hessell, A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 (2007), 101–104.
46. 46 Barouch, D.H., et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349 (2015), 320–324.
47. 47 Chung, A.W., et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med., 6, 2014, 228ra238.
48. 48 Yates, N.L., et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med., 6, 2014, 228ra239.
49. 49 Chung, A.W., et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 163 (2015), 988–998.
50. 50 Bergmann-Leitner, E.S., Leitner, W.W., Adjuvants in the driver's seat: how magnitude, type, fine specificity and longevity of immune responses are driven by distinct classes of immune potentiators. Vaccines (Basel) 2 (2014), 252–296.
51. 51 Khurana, S., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med, 2, 2010, 15ra15.
52. 52 Shukla, N.M., et al. Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer. PLoS ONE, 7, 2012, e43612.
53. 53 Vaccari, M., et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIV acquisition. Nat. Med. 22 (2016), 762–770.
54. 54 Chung, A.W., et al. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. AIDS 28 (2014), 2523–2530.
55. 55 Mahan, A.E., et al. Antigen-specific antibody glycosylation is regulated via vaccination. PLoS Pathog., 12, 2016, e1005456.
56. 56 Kaneko, Y., et al. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006), 670–673.
57. 57 Selman, M.H., et al. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics, 11, 2012, M111014563.
58. 58 Draper, S.J., Heeney, J.L., Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8 (2010), 62–73.
59. 59 Davies, J., et al. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 74 (2001), 288–294.
60. 60 Benhnia, M.R., et al. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J. Virol. 83 (2009), 1201–1215.
61. 61 Benhnia, M.R., et al. Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J. Virol. 87 (2013), 1569–1585.
62. 62 Reuveny, S., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69 (2001), 2888–2893.
63. 63 Abboud, N., et al. A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 207 (2010), 2395–2405.
64. 64 Bournazos, S., et al. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J. Clin. Invest. 124 (2014), 725–729.
65. 65 Moldt, B., et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 18921–18925.
66. 66 Pegu, A., et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med, 6, 2014, 243ra288.
67. 67 Mascola, J.R., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 (2000), 207–210.
68. 68 Barouch, D.H., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503 (2013), 224–228.
69. 69 Hessell, A.J., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15 (2009), 951–954.
70. 70 Moldt, B., et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86 (2012), 6189–6196.
71. 71 DiLillo, D.J., et al. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20 (2014), 143–151.
72. 72 Caskey, M., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522 (2015), 487–491.
73. 73 Schoofs, T., et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352 (2016), 997–1001.
74. 74 Cartron, G., et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004), 2635–2642.
75. 75 DiLillo, D.J., Ravetch, J.V., Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161 (2015), 1035–1045.
76. 76 Wang, T.T., et al. Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell 162 (2015), 160–169.
77. 77 Corti, D., et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351 (2016), 1339–1342.
78. 78 Qiu, X., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514 (2014), 47–53.
79. 79 Wilson, J.A., et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287 (2000), 1664–1666.
80. 80 Qiu, X., et al. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med, 8, 2016, 329ra333.
81. 81 Henry Dunand, C.J., et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe 19 (2016), 800–813.
82. 82 Strasser, R., et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6 (2008), 392–402.
83. 83 Zeitlin, L., et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 20690–20694.
84. 84 Hiatt, A., et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 5992–5997.
85. 85 Umana, P., et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17 (1999), 176–180.
86. 86 Cheeseman, H.M., et al. Expression profile of human Fc receptors in mucosal tissue: implications for antibody-dependent cellular effector functions targeting HIV-1 transmission. PLoS ONE, 11, 2016, e0154656.
87. 87 Ko, S.Y., et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514 (2014), 642–645.
88. 88 Gunn, B.M., et al. Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunol., 2016, 10.1038/mi.2016.8 Published online March 9, 2016.
89. 89 Anthony, R.M., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008), 373–376.
90. 90 Schwab, I., et al. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J. Immunol. 42 (2012), 826–830.
91. 91 Sondermann, P., et al. General mechanism for modulating immunoglobulin effector function. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 9868–9872.
92. 92 Clark, M.R., et al. Molecular basis for a polymorphism involving Fc receptor II on human monocytes. J. Immunol. 143 (1989), 1731–1734.
93. 93 Ravetch, J.V., Perussia, B., Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J. Exp. Med. 170 (1989), 481–497.
94. 94 Bruhns, P., et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113 (2009), 3716–3725.
95. 95 Bournazos, S., et al. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin. Exp. Immunol. 157 (2009), 244–254.
96. 96 Morell, A., et al. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49 (1970), 673–680.
97. 97 Ferrara, C., et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 12669–12674.
98. 98 Shields, R.L., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002), 26733–26740.
99. 99 Anthony, R.M., et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475 (2011), 110–113.
100. 100 Quast, I., et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J. Clin. Invest. 125 (2015), 4160–4170.
101. 101 Pone, E.J., et al. BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-kappaB pathway. Nat. Commun., 3, 2012, 767.
102. 102 Wang, J., et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol. Cell Proteomics, 10, 2011, M110004655.